Discounted Cash Flow
Jazz Pharmaceuticals Plc.
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.5b | $396.8m | $582.7m | 26.7% | $6.56 |
| 2017 | $1.6b (8.8%) | $487.8m (22.9%) | $664.1m (14.0%) | 30.1% (13.0%) | $8.13 (23.9%) |
| 2018 | $1.9b (16.8%) | $447.1m (-8.4%) | $778.5m (17.2%) | 23.6% (-21.5%) | $7.45 (-8.4%) |
| 2019 | $2.2b (14.3%) | $523.4m (17.1%) | $736.3m (-5.4%) | 24.2% (2.4%) | $9.22 (23.8%) |
| 2020 | $2.4b (9.3%) | $238.6m (-54.4%) | $884.6m (20.2%) | 10.1% (-58.3%) | $4.28 (-53.6%) |
| 2021 | $3.1b (30.9%) | $-329.7m (-238.2%) | $750.9m (-15.1%) | -10.7% (-205.5%) | $-5.52 (-229.0%) |
| 2022 | $3.7b (18.3%) | $-224.1m (32.0%) | $1.2b (65.5%) | -6.1% (42.5%) | $-3.58 (35.1%) |
| 2023 | $3.8b (4.8%) | $414.8m (285.1%) | $1.1b (-14.1%) | 10.8% (276.7%) | $6.55 (283.0%) |
| 2024 | $4.1b (6.1%) | $560.1m (35.0%) | $1.4b (27.1%) | 13.8% (27.2%) | $9.06 (38.3%) |
| 2025 | $4.3b (4.9%) | $-356.1m (-163.6%) | $1.3b (-4.5%) | -8.3% (-160.6%) | $-5.84 (-164.5%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Values abbreviated: b = billions, m = millions, k = thousands.
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.